{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"MedTech Speed to Data","title":"Using Spatial Biology to Get Critical Data : 34","html":"","width":"100%","height":180,"duration":2141,"description":"Pictorlabs is a California-based startup developing a cloud-based platform that uses artificial intelligence to improve tissue sample analysis through virtual histological staining.In Episode #34 of the Speed to Data Podcast, Key Tech’s Andy Rogers speaks with Pictorlabs Chief Product Officer Raymond Kozikowski about his company’s all-digital approach to tissue sample testing.Need to know·       Histopathology — The visual analysis of stained tissue samples to diagnose cancer and other conditions.·       Tests have long turnaround times — Selection, preparation, and imaging can take as long as a day to return one test’s results to the physician.·       Tests are requested sequentially — The results of one test determine the next test in the decision tree, so physicians can’t order all the tests simultaneously.·       Cancer patients must wait — On average, there is a forty-day gap between biopsy and first treatment.The nitty-grittyAs Dr. Kozikowski explains, “Histopathology has traditionally been a chemistry-based testing paradigm. Every cancer case starts with a biopsy, and those tissues are transformed into data that inform the diagnosis and therapeutic options.”Pictorlabs’ solution uses one tissue sample to create a virtual stain that simultaneously generates results for dozens of tests within minutes. “What we’re doing is teaching AI algorithms the relationship between validated test results and the underlying signature from that unstained piece of tissue,” Dr. Kozikowski said. “From a single patient sample, you’re no longer limited to running one chemical-based test. You can run ten, twenty, thirty AI-based tests.”Although the company thought it faced a long march toward the clinical market, Pictorlabs found an opportunity in a different market.“There’s a really robust cancer research market, both the academic medical centers and the pharma companies. Where we really got traction wasn’t necessarily as a replacement [technology] but a complement to other...","thumbnail_url":"https://img.transistorcdn.com/D6hMCysuuZpZO9MQfRbgtr2o9UZ_Mtc0h1qVAxU8GII/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS83MGQ2/N2MwMDdmNTRmOTRl/M2Y0MTcyNjAwN2Mz/OWRlZi5qcGc.webp","thumbnail_width":300,"thumbnail_height":300}